Each year on February 4th, World Cancer Day empowers all of us to show support, raise our collective voice, take personal action and press our governments to do more.
Company recently showed positive data in cancer and graft versus host disease.
ALPN-202 combines dual checkpoint blockade action with T-cell costimulation
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202.
| Website: | www.alpineimmunesciences.com |
| Email: | jgraziano@troutgroup.com |
| Main Phone: | +1 206 788-4545 |
| Address: | 188 East Blaine Street |
| Address 2: | Suite 200 |
| State: | WA |
| City / Town: | Seattle |
| Country: | US |
| Postal Code: | 98102 |
| Exchange: | NSD |
| CEO: | Mitchell H. Gold |
| Employees: | 53 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Each year on February 4th, World Cancer Day empowers all of us to show support, raise our collective voice, take personal action and press our governments to do more.
Company recently showed positive data in cancer and graft versus host disease.
ALPN-202 combines dual checkpoint blockade action with T-cell costimulation
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2021 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
